Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 605

Results For "AI"

8746 News Found

PIB: Pharmaceutical industry in Maharashtra
Policy | August 03, 2022

PIB: Pharmaceutical industry in Maharashtra

The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.


PIB: Pharma companies manufacturing generic medicine
Policy | August 03, 2022

PIB: Pharma companies manufacturing generic medicine

Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.


PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.
Policy | August 03, 2022

PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.

India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.


USFDA issues 3 observations for Aurobindo Pharma’s Unit XI
Drug Approval | August 03, 2022

USFDA issues 3 observations for Aurobindo Pharma’s Unit XI

The company has responded to the warning letter and carried out the committed corrections.


Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
News | August 02, 2022

Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.


Thyrocare Technologies posts Q1FY23 consolidated PAT at Rs. 21.73 Cr
News | August 02, 2022

Thyrocare Technologies posts Q1FY23 consolidated PAT at Rs. 21.73 Cr

The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.


Statement from Krsnaa Diagnostics on IT survey
News | August 02, 2022

Statement from Krsnaa Diagnostics on IT survey

The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.


UBC acquires Examoto
Biotech | August 02, 2022

UBC acquires Examoto

With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry


Cipla posts Q1FY23 consolidated PAT at Rs. 686.40 Cr
News | July 31, 2022

Cipla posts Q1FY23 consolidated PAT at Rs. 686.40 Cr

he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.